Open an account

Oncology Institute

STLN · NASDAQ

$6.63+$0.17 (+2.63%)TodayMarket closed ·
Prev close $6.46

About STLN

The Oncology Institute, Inc. provides cancer care treatment services. The company is headquartered in Cerritos, California and currently employs 641 full-time employees. The company went IPO on 2020-03-13. The firm manages community-based oncology practices which serve patients at approximately 86 clinic locations across 16 markets and five states throughout the United States. The firm's segment includes patient services, dispensary, and clinical trials & other. Its managed clinics provide a range of medical oncology services, including physician services, in-house infusion, radiation, and programs like outpatient blood product transfusions, along with 24/7 patient support. The Company, through TOI Clinical Research, LLC (TCR), provides and manages clinical trial services and research for the benefit of cancer patients. The firm also provides management services to over 14 clinic locations owned by independent oncology practices. The firm and its affiliated providers have contractual relationships with payors serving a variety of patients, including Medicare Advantage (MA), Medicaid, and commercial patients.

Employees
641
Headquarters
Cerritos, California
Listed
Mar 13, 2020
Sector
Health Care
Industry
Health Care Providers & Services
Website
theoncologyinstitute.com

STLN key statistics

Market cap
662.89M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.20M
Volume
1.10M
Open price
$6.48
High today
$6.86
Low today
$6.39
52 Week high
$7.13
52 Week low
$2.32

Oncology Institute (STLN) at a glance

Oncology Institute (STLN) last traded at $6.63, with a market cap of 662.89M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $6.39 and $6.86. The current price is 3.7% above the day's low and 3.4% below its high.

Volume so far is 1.10M shares, in line with the average of 1.20M shares a day.

Over the past year Oncology Institute has ranged from $2.32 to $7.13, and now sits 90% of the way up that range.

Oncology Institute met or beat analyst EPS estimates in 2 of the last 8 quarters. In Q2 FY26 it reported -$0.08 per share against an estimate of -$0.0653.

The average analyst price target is $9.18, 38.5% above the current price, from 1 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 1 analyst rating say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 7 analystsAvg $9.18
Low
$7.07
Now
$6.63
High
$11.55

STLN earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 2 of the last 8 quarters, by 54.7% on average.

  1. Q2 FY24: reported -$0.17 per share against an estimate of -$0.102
  2. Q3 FY24: reported -$0.18 per share against an estimate of -$0.0612
  3. Q1 FY25: reported -$0.17 per share against an estimate of $0.00
  4. Q2 FY25: reported -$0.15 per share against an estimate of -$0.1326
  5. Q3 FY25: reported -$0.14 per share against an estimate of -$0.1156
  6. Q4 FY25: reported -$0.06 per share against an estimate of -$0.0918
  7. Q1 FY26: reported -$0.02 per share against an estimate of -$0.0791
  8. Q2 FY26: reported -$0.08 per share against an estimate of -$0.0653

STLN news

  • 12 Health Care Stocks Moving In Friday's Intraday Session

  • 12 Health Care Stocks Moving In Friday's Pre-Market Session

Similar companies

Companies in the same industry as Oncology Institute

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.